Drugs / Target CD7 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04860817 | Dec 2021 → Apr 2023 | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Target CD7 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04860817 ↗ |
| Modality | Cell therapy | “CAR-T cells are immune cells that are engineered to target specific cell markers.” NCT04860817 ↗ |
| Route | Intravenous | “infusion of the CAR-T cells via a tube into the vein” NCT04860817 ↗ |